XLRNライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 1月 1970 @ 09:00):

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases...

Stats
本日の出来高	7.88M
平均出来高	1.27M
時価総額	0.00
EPS	$-1.160 ( 2021-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$2.64 (1.48%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-19	Zakrzewski Joseph S	Sell	34 499	Common Stock
2021-11-19	Zakrzewski Joseph S	Sell	10 000	Option to Purchase Common Stock
2021-11-19	Zakrzewski Joseph S	Sell	7 500	Option to Purchase Common Stock
2021-11-19	Zakrzewski Joseph S	Sell	7 500	Option to Purchase Common Stock
2021-11-19	Zakrzewski Joseph S	Sell	10 000	Option to Purchase Common Stock

INSIDER POWER
0.00
Last 100 transactions
Buy: 155 406 \| Sell: 743 673

ボリューム相関

長: 0.40 (neutral)

短: 0.62 (weak)

Signal:(71.182) Neutral

Acceleron Pharma Inc 相関

10 最も正の相関
APAC	0.971
THCPU	0.97
WTMA	0.97
ALGN	0.966
CRUS	0.963
ALGM	0.961
ATRS	0.961
IQ	0.96
NVAC	0.96
BLDR	0.959

10 最も負の相関
NAKD	-0.958
PROC	-0.953
MTEX	-0.949
AHPI	-0.949
GRIN	-0.946
TRIT	-0.94
PIII	-0.938
LCAP	-0.935
CYTO	-0.935
LAWS	-0.934

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Acceleron Pharma Inc 相関 - 通貨/商品

-0.74
( moderate negative )

-0.78
( moderate negative )

0.52
( weak )

-0.74
( moderate negative )

0.05
( neutral )

0.79
( moderate )

Acceleron Pharma Inc 財務諸表

Annual	2020
収益:	$92.52M
総利益:	$0.00 (0.00 %)
EPS:	$-2.92

FY	2020
収益:	$92.52M
総利益:	$0.00 (0.00 %)
EPS:	$-2.92

FY	2019
収益:	$73.99M
総利益:	$0.00 (0.00 %)
EPS:	$-2.38

FY	2018
収益:	$13.99M
総利益:	$0.00 (0.00 %)
EPS:	$-2.59

Financial Reports:

No articles found.

Acceleron Pharma Inc

Acceleron Pharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers luspatercept-aamt for the treatment of anemia in adult patients with beta-thalassemia under the REBLOZYL name. The company also develops luspatercept-aamt for the treatment of myelodysplastic syndromes and myelofibrosis; Sotatercept for the treatment of patients with pulmonary arterial hypertension; and ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with Charcot-Marie-Tooth disease. In addition, it has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.